Robert Wood Johnson Medical School
Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States12 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The PERSEVERE Study | Embolism, Embolism and Thrombosis, Pulmonary Thromboembolisms, cardiovascular disorder, lung disorder, pulmonary embolism, respiratory system disorder, vascular disorder | Recruiting | Not applicable | 2026-10-08 | NCT06588634 | |
| Continued Access to the Endogenex System for Participants in the ReCET Pivotal Study | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Enrolling by invitation | Not applicable | 2026-09-24 | NCT07197788 | |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | Skin Diseases, Papulosquamous, Skin and Connective Tissue Diseases, Spondylarthritis, Spondylarthropathies, arthritic joint disease, arthropathy, autoimmune disease, bone disorder, connective tissue disorder, immune system disorder, juvenile idiopathic arthritis, musculoskeletal system disorder, negative rheumatoid factor polyarthritis, psoriasis, psoriatic arthritis, rheumatic disorder, skin disorder, spondylitis, vertebral column disorder | Recruiting | Not stated | 2026-08-27 | NCT02418442 | |
| Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | Arterial Occlusive Diseases, Dyslipidemias, Hypercholesterolemia, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, hyperlipidemia, metabolic disease, vascular disorder | Active, not recruiting | Phase 3 | 2026-08-25 | NCT05030428 | |
| Multicenter ACL Revision Study (MARS) | Anterior Cruciate Ligament Injuries, Knee Injuries, Leg Injuries, injury | Active, not recruiting | Not stated | 2026-08-24 | NCT00625885 | |
| Platform Clinical Study for Conquering Scleroderma | Skin and Connective Tissue Diseases, connective tissue disorder, diffuse scleroderma, interstitial lung disease, lung disorder, respiratory system disorder, scleroderma, skin disorder, systemic sclerosis | Recruiting | Phase 2 | 2026-08-18 | NCT06195072 | |
| Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis | Body Weight, CNS demyelinating autoimmune disease, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Thinness, autoimmune disease, autoimmune disorder of the nervous system, demyelinating disease, immune system disorder, multiple sclerosis, nervous system disorder | Active, not recruiting | Phase 3 | 2026-08-10 | NCT01892722 | |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | Nutritional and Metabolic Diseases, diabetes mellitus, endocrine system disorder, glucose metabolism disease, metabolic disease, type 2 diabetes mellitus | Active, not recruiting | Not applicable | 2026-08-05 | NCT06267391 | |
| Pelacarsen Roll-over Extension Program | Arterial Occlusive Diseases, arteriosclerosis disorder, atherosclerosis, atherosclerotic cardiovascular disease, cardiovascular disorder, vascular disorder | Recruiting | Phase 3 | 2026-07-29 | NCT06875973 | |
| A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis | Myasthenia Gravis, Ocular, Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-07-02 | NCT06558279 | |
| Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD | Parkinson disease, basal ganglia disorder, brain disorder, central nervous system disorder, movement disorder, nervous system disorder, neurodegenerative disease, parkinsonian disorder, synucleinopathy | Active, not recruiting | Phase 2 | 2026-05-13 | NCT05819359 | |
| Enhancing Screening Practices for BE | Barrett esophagus, Digestive System Diseases, digestive system disorder, esophageal disorder, neoplasm, precancerous condition | Not yet recruiting | Not applicable | 2026-05-05 | NCT07335445 |